Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature

A 69-year-old man with stage IIIB lung adenocarcinoma received durvalumab following chemoradiotherapy. The prescribed dose was 50 Gy in 2 Gy fractions, and the maximum spinal cord dose was 40 Gy. After three cycles of durvalumab, he experienced bladder and rectal disturbance, muscle weakness in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubo, Katsumaro, Wadasaki, Koichi, Yamane, Hiroaki, Doi, Mihoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545180/
https://www.ncbi.nlm.nih.gov/pubmed/31218187
http://dx.doi.org/10.1007/s13691-019-00367-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545180/
https://www.ncbi.nlm.nih.gov/pubmed/31218187
http://dx.doi.org/10.1007/s13691-019-00367-5

Ejemplares similares